  |
|
08.03.2010 FDA Approves NerPharMa to Manufacture Cell
Therapeutics' Drug Pixantrone
Cell Therapeutics, Inc.
("CTI") (Nasdaq and MTA: CTIC) today announced
that the U.S. Food and Drug Administration
("FDA") has completed its inspection of the
facility at NerPharMa (a pharmaceutical
manufacturing company belonging to Nerviano
Medical Sciences Srl, in Nerviano, Italy), which
manufactures the CTI's drug pixantrone and
has found the site in compliance... |
 |
|
|
|
  |
|
05.03.2010 MOLOGEN AG receives approval for clinical study with
cancer drug MGN1703
The
Berlin biotech company
MOLOGEN AG has received
approval from the competent German and Austrian health authorities at the
Paul Ehrlich Institute and the Federal Office for Safety in Health Care (“Bundesamt
für Sicherheit im Gesundheitswesen”), respectively, to conduct a phase 2
study on the cancer drug MGN1703. MGN1703 is a DNA-based immunomodulator,
which is being... |
|
|
|
|
|
|
|
03.03.2010 ACADIA Pharmaceuticals to Announce Fourth Quarter and
Full Year 2009 Financial Results on March 9, 2010
ACADIA
Pharmaceuticals Inc.
(Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug
discovery and clinical development of novel
treatments for central nervous system disorders,
today announced that it will report its
unaudited financial results for the fourth
quarter and year ended December 31, 2009 on
Tuesday, March 9, 2010, after the U.S. financial
markets close. ACADIA's management will host a
conference call and webcast on Tuesday, March 9,
2010, at 5:00 p.m. Eastern Time to discuss
ACADIA's financial results and development
programs.
|
 |
|
|
|
|
|
|
03.03.2010 InVitria Optimizes
Hybridoma Cell Culture with New Product Zap-Hybridoma
InVitria’s
launch of Zap-Hybridoma provides a powerful solution for
hybridoma cell culture. Zap-Hybridoma was created to
improve monoclonal antibody productivity and deliver
easier purification of the target product. |
 |
|
|
|
  |
|
|
02.03.2010 BNC210 Clinical Trial Results Confirm Safety
and Indicate Reduced Stress Hormone Levels
Bionomics Limited
(ASX: BNO) today announced the final results of
its Phase Ia clinical trial of BNC210. Dosing of healthy
male volunteers in stage 2 of the Phase Ia
trial, which was conducted at the Pain and
Anaesthesia Research Clinic (PARC) within the
Royal Adelaide Hospital, was completed on
schedule at the end of last year.
|
 |
|
|
|
|
|
|
|
All rights reserved